The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
|Videos|July 7, 2017
Dr. Huffman on Survival Analysis of Patients With Pseudopapillary Tumors of the Pancreas
Author(s)Brandon Huffman, MD
Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.
Advertisement
Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.
Solid pseudopapillary tumors make up only 2% of all pancreatic tumors. Using the National Cancer Database, the outcomes of patients with solid pseudopapillary tumors were collected and evaluated.
Advertisement
Related to this article
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
HR-Positive/HER2-Negative Metastatic Breast Cancer: Treatment Sequencing After Adjuvant Endocrine Therapy and Transitioning Beyond Endocrine-Based Approaches
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
5